Cabaletta Bio, Inc.

CABA · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
128
SEC Filings

Business Summary

PART I . Overview We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA , or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentia...

Next Earnings

Q2 FY2026 — expected 2026-09-12

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionCABAdiscussed_in_filing Cybersecurity
topic_mentionCABAdiscussed_in_filing Cybersecurity
topic_mentionCABAdiscussed_in_filing Platform & Ecosystem
topic_mentionCABAdiscussed_in_filing Platform & Ecosystem

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-232025-12-310001759138-26-000011EDGAR111K words
2025-03-312024-12-310000950170-25-047201EDGAR—
2024-03-212023-12-310000950170-24-034422EDGAR—
2023-03-162022-12-310000950170-23-008298EDGAR—
2022-03-172021-12-310001564590-22-010726EDGAR—
2021-03-162020-12-310001564590-21-013329EDGAR—
2020-03-302019-12-310001564590-20-013929EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001193125-25-273280EDGAR79K words
2025-08-072025-06-300000950170-25-104573EDGAR—
2025-05-152025-03-310000950170-25-071971EDGAR—
2024-11-142024-09-300000950170-24-126733EDGAR—
2024-08-082024-06-300000950170-24-093325EDGAR—
2024-05-152024-03-310000950170-24-060045EDGAR—
2023-11-092023-09-300000950170-23-061528EDGAR—
2023-08-102023-06-300000950170-23-040966EDGAR—
2023-05-112023-03-310000950170-23-020849EDGAR—
2022-11-102022-09-300000950170-22-024168EDGAR—
2022-08-112022-06-300000950170-22-016650EDGAR—
2022-05-122022-03-310001564590-22-019677EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-230001759138-26-000010EDGAR3K words
2026-01-120001193125-26-009819EDGAR—
2025-11-100001193125-25-273272EDGAR—
2025-10-290001193125-25-254610EDGAR—
2025-10-270001193125-25-250676EDGAR—
2025-10-090001193125-25-235533EDGAR—
2025-09-030001759138-25-000007EDGAR—
2025-08-070000950170-25-104570EDGAR—
2025-06-120001193125-25-139517EDGAR—
2025-06-110001193125-25-138737EDGAR—

128 total filings indexed. 99 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001759138
TickerCABA
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 2dd23dfc20885b7fff7a81b1dbc0cf4c40196b351d6be42a2d0af1c9b1deed50
parent: f6d044ef22881ff30d16ca242ebdc33e4d66773b0804cadecb5c9b32ac4d7b4f
content hash: bd34da87873e51b7217b53007ebf9085e3e96902f72b9bb11baa3e0c97d76a83
signed: 2026-04-13T04:44:10.462Z
sources: 19 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf